These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
708 related articles for article (PubMed ID: 8415756)
41. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. McCarron MO; Nicoll JA; Stewart J; Ironside JW; Mann DM; Love S; Graham DI; Dewar D J Neuropathol Exp Neurol; 1999 Jul; 58(7):711-8. PubMed ID: 10411341 [TBL] [Abstract][Full Text] [Related]
42. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Castano EM; Prelli F; Wisniewski T; Golabek A; Kumar RA; Soto C; Frangione B Biochem J; 1995 Mar; 306 ( Pt 2)(Pt 2):599-604. PubMed ID: 7534068 [TBL] [Abstract][Full Text] [Related]
43. A 3'-UTR polymorphism in the oxidized LDL receptor 1 gene increases Abeta40 load as cerebral amyloid angiopathy in Alzheimer's disease. Shi J; Tian J; Pritchard A; Lendon C; Lambert JC; Iwatsubo T; Mann DM Acta Neuropathol; 2006 Jan; 111(1):15-20. PubMed ID: 16328515 [TBL] [Abstract][Full Text] [Related]
44. Genetic-morphologic association study: association between the low density lipoprotein-receptor related protein (LRP) and cerebral amyloid angiopathy. Christoforidis M; Schober R; Krohn K Neuropathol Appl Neurobiol; 2005 Feb; 31(1):11-9. PubMed ID: 15634227 [TBL] [Abstract][Full Text] [Related]
45. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Mann DM; Pickering-Brown SM; Takeuchi A; Iwatsubo T; Am J Pathol; 2001 Jun; 158(6):2165-75. PubMed ID: 11395394 [TBL] [Abstract][Full Text] [Related]
46. The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype. Pletnikova O; Kageyama Y; Rudow G; LaClair KD; Albert M; Crain BJ; Tian J; Fowler D; Troncoso JC Neurobiol Aging; 2018 Nov; 71():72-80. PubMed ID: 30099348 [TBL] [Abstract][Full Text] [Related]
47. Apolipoprotein E genotype and its pathological correlation in Chinese Alzheimer's disease with late onset. Chen L; Baum L; Ng HK; Chan LY; Pang CP Hum Pathol; 1999 Oct; 30(10):1172-7. PubMed ID: 10534164 [TBL] [Abstract][Full Text] [Related]
49. Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E's protective effects towards amyloid-beta-induced toxicity. de Jager M; Drukarch B; Hofstee M; Brevé J; Jongenelen CA; Bol JG; Wilhelmus MM J Neurochem; 2015 Sep; 134(6):1116-28. PubMed ID: 26088696 [TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits. Navarro A; Del Valle E; Astudillo A; González del Rey C; Tolivia J Exp Neurol; 2003 Dec; 184(2):697-704. PubMed ID: 14769361 [TBL] [Abstract][Full Text] [Related]
51. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison. Jeynes B; Provias J Acta Neuropathol; 2006 Oct; 112(4):417-27. PubMed ID: 16830133 [TBL] [Abstract][Full Text] [Related]
52. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Montine TJ; Markesbery WR; Zackert W; Sanchez SC; Roberts LJ; Morrow JD Am J Pathol; 1999 Sep; 155(3):863-8. PubMed ID: 10487843 [TBL] [Abstract][Full Text] [Related]
54. Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Ghebremedhin E; Thal DR; Schultz C; Braak H Neurosci Lett; 2002 Mar; 320(1-2):25-8. PubMed ID: 11849755 [TBL] [Abstract][Full Text] [Related]
55. Biological Signatures of Alzheimer's Disease. Sharma P; Sharma A; Fayaz F; Wakode S; Pottoo FH Curr Top Med Chem; 2020; 20(9):770-781. PubMed ID: 32108008 [TBL] [Abstract][Full Text] [Related]
56. Apolipoprotein E, smooth muscle cells and the pathogenesis of cerebral amyloid angiopathy: the potential role of impaired cerebrovascular A beta clearance. Prior R; Wihl G; Urmoneit B Ann N Y Acad Sci; 2000 Apr; 903():180-6. PubMed ID: 10818506 [TBL] [Abstract][Full Text] [Related]
57. Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope. Nishiyama E; Iwamoto N; Ohwada J; Arai H Brain Res; 1997 Mar; 750(1-2):20-4. PubMed ID: 9098525 [TBL] [Abstract][Full Text] [Related]
58. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Evans KC; Berger EP; Cho CG; Weisgraber KH; Lansbury PT Proc Natl Acad Sci U S A; 1995 Jan; 92(3):763-7. PubMed ID: 7846048 [TBL] [Abstract][Full Text] [Related]
59. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Richey PL; Siedlak SL; Smith MA; Perry G Biochem Biophys Res Commun; 1995 Mar; 208(2):657-63. PubMed ID: 7695621 [TBL] [Abstract][Full Text] [Related]
60. Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele. Pahnke J; Walker LC; Schroeder E; Vogelgesang S; Stausske D; Walther R; Warzok RW Acta Neuropathol; 2003 Jan; 105(1):25-9. PubMed ID: 12471457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]